NuVasive, Inc. (NUVA) EPS Estimated At $0.56

February 25, 2018 - By Migdalia James

 NuVasive, Inc. (NUVA) EPS Estimated At $0.56
Investors sentiment decreased to 0.95 in Q3 2017. Its down 0.28, from 1.23 in 2017Q2. It turned negative, as 67 investors sold NuVasive, Inc. shares while 69 reduced holdings. 47 funds opened positions while 82 raised stakes. 53.88 million shares or 3.45% less from 55.81 million shares in 2017Q2 were reported.
Keybank National Association Oh owns 9,159 shares. Victory Cap Mgmt reported 166,540 shares. Geode Capital Limited Company invested in 449,237 shares or 0.01% of the stock. 771,135 were accumulated by Jana Partners Ltd. Prudential Financial Inc, a New Jersey-based fund reported 34,586 shares. Hbk Invs L P owns 21,630 shares for 0.01% of their portfolio. Diversified Trust invested in 0.03% or 7,728 shares. 178,808 were reported by Gamco Invsts Et Al. Thrivent For Lutherans holds 519,170 shares. Advisory Services Net invested 0% in NuVasive, Inc. (NASDAQ:NUVA). Rothschild Asset Mgmt reported 528,023 shares. Citigroup accumulated 20,251 shares or 0% of the stock. State Teachers Retirement Sys stated it has 0% of its portfolio in NuVasive, Inc. (NASDAQ:NUVA). Koch Industries stated it has 16,673 shares or 0.22% of all its holdings. Gilder Gagnon Howe And Ltd Co holds 22,666 shares or 0.02% of its portfolio.

Analysts expect NuVasive, Inc. (NASDAQ:NUVA) to report $0.56 EPS on February, 26 after the close.They anticipate $0.03 EPS change or 5.66 % from last quarter’s $0.53 EPS. NUVA’s profit would be $28.54 million giving it 21.37 P/E if the $0.56 EPS is correct. After having $0.52 EPS previously, NuVasive, Inc.’s analysts see 7.69 % EPS growth. The stock increased 1.87% or $0.88 during the last trading session, reaching $47.86. About 477,685 shares traded. NuVasive, Inc. (NASDAQ:NUVA) has risen 33.31% since February 25, 2017 and is uptrending. It has outperformed by 16.61% the S&P500.

NuVasive, Inc. (NASDAQ:NUVA) Ratings Coverage

Among 22 analysts covering Nuvasive Inc. (NASDAQ:NUVA), 17 have Buy rating, 0 Sell and 5 Hold. Therefore 77% are positive. Nuvasive Inc. has $9000 highest and $56 lowest target. $72.50’s average target is 51.48% above currents $47.86 stock price. Nuvasive Inc. had 65 analyst reports since July 29, 2015 according to SRatingsIntel. BMO Capital Markets maintained NuVasive, Inc. (NASDAQ:NUVA) on Thursday, August 31 with “Buy” rating. Canaccord Genuity maintained the shares of NUVA in report on Tuesday, September 19 with “Buy” rating. As per Monday, October 9, the company rating was maintained by RBC Capital Markets. The company was initiated on Monday, September 14 by Morgan Stanley. The firm has “Equal-Weight” rating given on Tuesday, July 25 by Morgan Stanley. As per Tuesday, September 22, the company rating was initiated by UBS. Bank of America upgraded the stock to “Neutral” rating in Friday, December 11 report. The firm has “Buy” rating given on Friday, July 28 by Jefferies. The firm has “Outperform” rating given on Thursday, July 30 by Northland Capital. BMO Capital Markets upgraded it to “Outperform” rating and $64 target in Tuesday, October 6 report.

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. The company has market cap of $2.44 billion. The Company’s products focus on applications for spine fusion surgery, including biologics used for spinal fusion process. It has a 41.12 P/E ratio. The companyÂ’s principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

More notable recent NuVasive, Inc. (NASDAQ:NUVA) news were published by: which released: “NuVasive: Prognosis Is For A 25% Gain” on February 20, 2018, also with their article: “International Business Aids NuVasive, Pricing Woe Remains” published on February 22, 2018, published: “NuVasive (NUVA) Appoints John DeFord to Board” on February 08, 2018. More interesting news about NuVasive, Inc. (NASDAQ:NUVA) were released by: and their article: “NuVasive, Inc (NUVA): Prognosis Is For A 25%+ Gain” published on February 19, 2018 as well as‘s news article titled: “NuVasive SpineTRACK Registry Named Qualified Clinical Data Registry By Centers …” with publication date: February 20, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: